DARZALEX (daratumumab): Reviews and patient testimonials
Medication indications
DARZALEX 20 mg/mL concentrate for solution for infusion
DARZALEX is indicated:
• as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy.
• in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy
Route of administration: Injectable
Molecule: daratumumab
Patients' opinions on DARZALEX
In brief
General satisfaction level: 4.00/10 Learn more
Treatment's effectiveness: 5.50/10 Learn more
Ease of use: 4.00/10 Learn more
Adherence to prescription: 10.00/10 Learn more
Detected side effects: 4.00/10 Learn more
Improvement in the quality of life: 4.00/10 Learn more
1 = Not at all satisfied
10 = Extremely satisfied
1 = Not at all satisfied
10 = Extremely satisfied
1 = Not at all satisfied
10 = Extremely satisfied
1 = Never
10 = Always
1 = Not at all important
10 = Extremely important
1 = Not at all satisfied
10 = Extremely satisfied
Tips and advice of the community